Health & Medical · Brand U-52707
Medicap Pharmacy franchise research
Costs by format. Disclosure context. Historical loan evidence. Know what is captured and what still needs diligence.
Open your research shortlistSource: FDD issued Not captured · SBA data through Jun 30, 2026 · Automated extraction, not human-reviewed · View all sources
- Investment
- $513,050 to $895,653 New Store · +1 more
- Royalty
- 3% 3% of gross sales, invoiced and due within 30 days (or on the 15th of each month if not on the fixed-fee option)
- Working capital
- $175,000-$245,000 (New Store) or $125,000-$200,000 (Conversion) for estimated operating expenses during the first 3 months, including working capital, payroll and fees payable to Medicap; low estimate excludes a pharmacist's salary (assumes owner/operator) and excludes finance charges/interest.
- Units
- 59 -4 net in June 30, 2025
- SBA loans approved
- 1 FY2021 to FY2026 YTD
- SBA charge-off share
- 0.00% historical, not a failure rate
Investment by format
| Format | Disclosed range |
|---|---|
| New Store | $513,050 to $895,653 |
| Conversion | $130,000 to $546,653 |
Format-specific estimates only. Do not combine one format's minimum with another format's maximum.
Investment sourceFDD p.25 ↗
Franchise fees and ongoing costs
- Franchise fee
- $0 · Extracted Item 5 scalar range, not a universal minimum or maximum; formats, eligibility, discounts and waivers require original-filing review.
- Royalty
- 3% · $599 · 3% of gross sales, invoiced and due within 30 days (or on the 15th of each month if not on the fixed-fee option)
- Marketing contribution
- Not captured
- Technology fee
- Not captured
- Other fees
- Reimbursement Consulting Service $255-$300/mo; Cardinal Health Inventory Optimization Solution $325/mo; Pharmacy Marketing Advantage (PMA) digital/communication/reputation packages $69-$1,015/mo (all optional Retail Solutions)
- Working capital (FDD Item 7)
- $175,000-$245,000 (New Store) or $125,000-$200,000 (Conversion) for estimated operating expenses during the first 3 months, including working capital, payroll and fees payable to Medicap; low estimate excludes a pharmacist's salary (assumes owner/operator) and excludes finance charges/interest.
Fees sourceFDD p.19 ↗
Working capital is drawn from Item 7. The Investment source below locates the investment section, not an independently verified working-capital scalar.
Investment sourceFDD p.25 ↗
Franchise fee sourceFDD · page not captured ↗
Financial performance: Item 19
- Item 19 captured
- No
- Metric / basis
- none - Medicap makes no financial performance representations
- Reporting period
- Not captured
- Sample
- Not captured
- Reported average
- Not captured
- Reported median
- Not captured
Owner income is not captured. Gross sales and EBITDA are not owner pay. Results depend on the disclosed metric, sample and period; consult the full filing.
Item 19 performance sourceFDD p.48 ↗
Unit growth: Item 20
- Reporting year
- June 30, 2025
- Scope
- franchised outlets
- Starting outlets
- 63
- Year-end outlets
- 59
- Net change
- -4
- Derivation
- ending minus starting outlets
- Openings
- 0
- Terminations
- 1
- Non-renewals
- 1
- Other closures
- 2
- Reacquisitions
- 0
- Transfers
- 0
Transfers are not closures. Net change is ending minus starting outlets for the stated scope and year, or complete openings less terminations, non-renewals, other closures and reacquisitions. Missing inputs stay unknown.
Unit growth sourceFDD p.48 ↗
SBA loan history
- Loan activity
- 1 approvals
- Activity window
- FY2021-FY2026 YTD; snapshot 2026-06-30
- Median SBA loan
- $673,000
- Median loan window
- FY2023-FY2026 YTD through 2026-06-30
- Median loan sample
- 1 loans
- Historical charge-off share
- 0.00%
- Cohort
- 7(a) FY2010-2019 approvals
- Numerator / denominator
- 0 / 13
- Formula
- CHGOFF / (PIF + CHGOFF + EXEMPT) × 100
This is a historical loan-level share, not a franchise failure probability or location survival rate. Loan size is not total investment. Other loan statuses are excluded from the seasoned denominator. Activity combines 7(a) and 504 approvals, excluding canceled and not-funded records; this is not a rolling five-year count. FY2024-25 franchise tags are sparse after directory suspension; fewer tagged loans do not establish brand decline. Recent charge-off cohorts are immature.
SBA loans sourceSBA data · Jun 30, 2026 ↗
Median loan amounts are financing context, not startup cost. The median window is separate from the seasoned charge-off cohort.
Median SBA loan sourceSBA data · Jun 30, 2026 ↗
Questions before you invest
How much does Medicap Pharmacy franchise cost?
New Store: $513,050 to $895,653; Conversion: $130,000 to $546,653 These are format-specific estimates, not a guaranteed cash requirement. Franchise fee: $0 · Extracted Item 5 scalar range, not a universal minimum or maximum; formats, eligibility, discounts and waivers require original-filing review..
Investment sourceFDD p.25 ↗
Franchise fee sourceFDD · page not captured ↗
How much do Medicap Pharmacy owners make?
Owner income is not captured. Gross sales and EBITDA are not owner pay. Item 19 metric: none - Medicap makes no financial performance representations. Sample: Not captured. Period: Not captured.
Item 19 performance sourceFDD p.48 ↗
What's the SBA charge-off rate for Medicap Pharmacy?
0.00%; numerator / denominator: 0 / 13. Historical 7(a) FY2010-2019 approvals; CHGOFF / (PIF + CHGOFF + EXEMPT) × 100, snapshot 2026-06-30. This is not a franchise failure probability. Median SBA loan: $673,000; window: FY2023-FY2026 YTD through 2026-06-30; sample: 1 loans. Median financing is not total investment.
SBA loans sourceSBA data · Jun 30, 2026 ↗
Median SBA loan sourceSBA data · Jun 30, 2026 ↗
Sources and data details
Every figure above links to the page of the filing it was read from. These are the document IDs, page pointers and checksums behind them, for anyone who wants to audit the data.
Show document IDs, page pointers and hashes
Original source · FDD issued: Not captured; Registry received: 09/22/2025
Document: 34802-202509-09; document SHA-256: 692a43b43191a40999f3a00b91ef9d445719938c7b946f8b60ec844ab27d1b23
PDF page: 19; pointer: scalar-page-match. Not independently reviewed.
Dataset generated: 2026-10-03T02:32:20.074756+00:00; dataset version: f8a919ba13aeff8e04da22842f084c7fb459e532543a173426eaa34a86deca5d
Original source · FDD issued: Not captured; Registry received: 09/22/2025
Document: 34802-202509-09; document SHA-256: 692a43b43191a40999f3a00b91ef9d445719938c7b946f8b60ec844ab27d1b23
PDF page: 25; pointer: scalar-page-match. Not independently reviewed.
Dataset generated: 2026-10-03T02:32:20.074756+00:00; dataset version: f8a919ba13aeff8e04da22842f084c7fb459e532543a173426eaa34a86deca5d
Original source · FDD issued: Not captured; Registry received: 09/22/2025
Document: 34802-202509-09; document SHA-256: 692a43b43191a40999f3a00b91ef9d445719938c7b946f8b60ec844ab27d1b23
PDF page: Not captured; pointer: source-known-page-unknown. Not independently reviewed.
Dataset generated: 2026-10-03T02:32:20.074756+00:00; dataset version: f8a919ba13aeff8e04da22842f084c7fb459e532543a173426eaa34a86deca5d
Enrichment generated: 2026-10-03T11:34:53.025030+00:00
Original source · FDD issued: Not captured; Registry received: 09/22/2025
Document: 34802-202509-09; document SHA-256: 692a43b43191a40999f3a00b91ef9d445719938c7b946f8b60ec844ab27d1b23
PDF page: 48; pointer: section-page-match. Not independently reviewed.
Dataset generated: 2026-10-03T02:32:20.074756+00:00; dataset version: f8a919ba13aeff8e04da22842f084c7fb459e532543a173426eaa34a86deca5d
Original source · FDD issued: Not captured; Registry received: 09/22/2025
Document: 34802-202509-09; document SHA-256: 692a43b43191a40999f3a00b91ef9d445719938c7b946f8b60ec844ab27d1b23
PDF page: 48; pointer: scalar-page-match. Not independently reviewed.
Dataset generated: 2026-10-03T02:32:20.074756+00:00; dataset version: f8a919ba13aeff8e04da22842f084c7fb459e532543a173426eaa34a86deca5d
Original source · SBA snapshot: 2026-06-30
Document: FOIA_7a_FY2010_FY2019_asof_260630.csv; document SHA-256: 01a3e2c7988a6f4052e53f218a309feb2ec2fe42887bebdc0fa94ac8b1024ade
PDF page: Not captured; pointer: raw-aggregate-recomputed. Not independently reviewed.
Dataset generated: 2026-10-03T02:32:20.074756+00:00; dataset version: f8a919ba13aeff8e04da22842f084c7fb459e532543a173426eaa34a86deca5d
Input document hashes: FOIA_7a_FY2010_FY2019_asof_260630.csv: 01a3e2c7988a6f4052e53f218a309feb2ec2fe42887bebdc0fa94ac8b1024ade; FOIA_7a_FY2020_Present_asof_260630.csv: 6c1e9132b5141a19f82bdc8ccafb86c9a01662461cad41ddb36a3cf409d8a4fe; FOIA_504_FY2010_Present_asof_260630.csv: 8c0e15414217254bcde2a253a8f17418b3dc65ce78dbc56cc1f1ab05c4a05ad4; code_map.csv: df55c53a0afc764ee1507d535a1924a3fab105a6daca0143ca56d9791d385d7b
Original source · SBA snapshot: 2026-06-30
Document: FOIA_7a_FY2020_Present_asof_260630.csv; document SHA-256: 6c1e9132b5141a19f82bdc8ccafb86c9a01662461cad41ddb36a3cf409d8a4fe
PDF page: Not captured; pointer: raw-median-recomputed. Not independently reviewed.
Dataset generated: 2026-10-03T02:32:20.074756+00:00; dataset version: f8a919ba13aeff8e04da22842f084c7fb459e532543a173426eaa34a86deca5d
Input document hashes: FOIA_7a_FY2020_Present_asof_260630.csv: 6c1e9132b5141a19f82bdc8ccafb86c9a01662461cad41ddb36a3cf409d8a4fe; code_map.csv: df55c53a0afc764ee1507d535a1924a3fab105a6daca0143ca56d9791d385d7b
Enrichment generated: 2026-10-03T11:34:53.025030+00:00
Program: 7(a); Amount column: GrossApproval